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S A @ E T A K
Early laryngeal cancer comprises T1 and T2 stages of the disease. Open functional operations achieve local control of
the disease in 90–95% of T1 patients and in 70–90% of T2 patients. Primary RT achieves local control in 85–94% of T1
tumors and in 70–80% of patients with T2 tumors. Introduction of endoscopic laser surgery resulted in further popular-
ization of preservation laryngeal surgery, whereby equally successful treatment results are achieved with minimal inva-
siveness. Quality of voice is also better after RT and laser resection. In the last century a golden standard of treatment of
advanced laryngeal cancer (T3/T4 stage) was total laryngectomy (TL) with neck dissection followed by adjuvant RT.
Overall 5 year survival was around 50%. Due to impact of TL on quality of life, »Larynx preservation strategy« (LPS)
was developed in the early '90 for advanced stages of the disease. Novel approach is an introduction of targeted therapy,
such as anti-EGFR monoclonal antibody, cetuximab. Concomitant cetuximab with RT achieves higher survival, and
better locoregional disease control in comparison to administration of single RT modality. Therefore non-surgical meth-
ods of treatment of advanced laryngeal carcinoma are constantly changing and improving as new chemotherapeutics are
being introduced into protocols. Uncritical enthusiasm with non-surgical methods of treatment resulted in higher inci-
dence of treatment toxicities, higher rates of »salvage surgery« with more frequent adverse effects. That resulted in a con-
sensus attempt around »LPS« project with reevaluation of clinical studies and uniform recommendations for future
studies. When choosing appropriate therapy for oncological patient, quality of life (QOL) is a special category to be taken
into account besides complications, pain, duration of treatment and overall benefit for the patient.
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Introduction
Larynx cancer is besides thyroid cancer the most com-
mon head and neck malignancy. There has been a con-
stant decline in its incidence due to numerous public
campaigns against smoking, however a relative increase
in the incidence has been noticed among younger people
caused by human papilloma virus infection (HPV)1,2.
Early laryngeal cancer comprises T1 and T2 stages of
the disease. Besides radiotherapy (RT), a functional la-
ryngeal surgery has developed in the '70 and comprises
many opened techniques (laryngofissure with cordec-
tomy, cricoepiglottopexy). Because of the low incidence of
metastasis in early laryngeal cancer, local control of the
disease is the most important prognostic factor. Opened
functional operations achieve local control of the disease
in 90–95% of T1 patients and in 70–90% of T2 patients
(with up to 95% of preserved larynges). The most com-
mon complications of treatment are granulations or ad-
hesions, aspirations and laryngeal edema. Primary RT
achieves local control in 85–94% of T1 tumors and in
70–80% of patients with T2 tumors. Parameters that
negatively impact the success of RT are: higher T stage,
prolonged time of RT, male sex, anemia prior to start of
RT, high tumor grade and daily radiation dose <2 Gray3.
Introduction of endoscopic laser surgery resulted in fur-
ther popularization of preservation laryngeal surgery,
whereby equally successful treatment results are achie-
ved with minimal invasiveness (local disease control in
80–90% of T1 tumors and 70–85% of T2 tumors with rate
of larynx preservation over 95%)4. Besides complications
connected to the removal of the tumor (granulations, ad-
hesions), specific complications connected to the tech-
niques of endoscopic laser procedures can occur (burns,
endotracheal tube ignition) which can be reduced to a
minimum by adherence to safety measures. Local con-
trol, overall survival and laryngeal speech preservation
rates are comparable with aforementioned methods
with a few exceptions. Patients with tumors invading the
anterior commissure show higher rates of tumor recur-
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rence after transoral approach in comparison to RT,
whereby T2 tumors with unfavorable localization are
best treated with an open approach.
RT and transoral resections have similar rates of com-
plications and at the lower rates than open approach.
Quality of voice is also better after RT and laser resec-
tion5,6.
In the last century a golden standard of treatment of
advanced laryngeal cancer (T3/T4 stage) was total laryn-
gectomy (TL) with neck dissection followed by adjuvant
RT. Overall 5 year survival was around 50%. For inopera-
ble carcinomas neoadjuvant RT was employed (66–76
Gy)7. Due to impact of TL on quality of life, »Larynx
preservation strategy« (LPS) was developed in the early
‘90 for advanced stages of the disease. It includes induc-
tion chemotherapy (ICT) followed by RT or concomitant
chemoradiotherapy (CCRT). The goal of such treatment
approach has not been only an increase in survival or
prolongation of disease free survival, but also a higher
percentage of patients with functioning larynx1.
»The Department of Veterans Affairs Laryngeal Can-
cer Study Group« (VALCSG) was the most important
and the first study to show that nonsurgical methods of
advanced laryngeal cancer treatment can achieve similar
results as TL with neck dissection followed by RT. ICT (5
fluorouracil and cisplatin) followed by RT, with »salvage
surgery« as an option in case of a weak response, achie-
ved 2 year survival of 68% in both cohorts as well as
lower incidence of local recurrence and distant metasta-
sis. The best accomplishment was a high rate of larynx
preservation in non-surgical group of patients (64%)8.
The »Radiation Oncology Group« study (RTOG 91–11)
compared all three modalities of »Larynx preservation
strategy« (RT, ICT, CCRT). Larynx preservation rate was
significantly higher in patients treated with CCRT (83%)
compared to those treated with RT (65.7%) and ICT
(70.5%). Locoregional control was also better in CCRT
arm. However no significant improvement in 5 year over-
all survival was noticed among arms although CCRT arm
had somewhat better prognosis (59.2% vs. 54% for other
two cohorts)9. Aforementioned studies have changed the
standard of treatment of advanced laryngeal carcinoma
patients, however a criticism due to flaws in study design
emerged. Among them is the fact that an advanced stage
was assigned to some patients according to the neck
stage, in spite of the lower laryngeal stage of the disease.
Therefore, patients with mobile vocal cords and candi-
dates for laryngeal functional surgery (42% of patients in
RTOG 91-11 study and 48% of patients in VALCSG
study) were grouped together with patients that required
TL. Comparison between these two studies revealed that
patients in RTOG 91-11 study had lower stage of the dis-
ease what could significantly impact overall survival and
larynx preservation rate1.
MAC-HNC (meta-analysis of chemotherapy in head
and neck cancer) was conducted in order to evaluate the
benefit of chemotherapy in treatment of head and neck
cancer (includes 93 randomized studies on over 17 000
patients). Results showed superiority of CCRT over ICT
in overall survival (3.5±3.1%), locoregional control (HR
=0.77) and event free survival (HR=0.81)10. Results of
treatment were similar for any chemotherapy agent ad-
ministered concomitantly with RT (only cisplatin, cispla-
tin/carboplatin in combination with 5-FU or other com-
bination of polychemotherapy that includes cisplatin or
5-FU). On the contrary monochemotherapy achieved
weaker responses and should not be a part of a routine
treatment. The only recommendable monochemothera-
py is cisplatin in combination with RT and dose of 100
mg/mL2,11. There is also a decline in therapy efficacy with
age, which can be explained by lower compliance and
more frequent and more serious adverse effects in ad-
vanced age patients. Conclusion of the analysis is that
CCRT presents the standard of treatment for advanced
laryngeal carcinoma with significant effect on locore-
gional disease, larynx preservation and overall survival,
if patients are receiving chemotherapy based on plati-
num agents or only cisplatin12.
Further development of each modality of LPS is also
interesting. In the phase III of GORTEC study taxane
was added to cisplatin-5-FU (PF) in classical ICT which
resulted in TPF protocol. It could achieve significantly
higher larynx preservation (63% vs. 41.4%), however
with significant adverse effects (3rd and 4th grade neu-
tropenia) and a need for prophylactic administration of
G-CSF or antibiotics13. Modification of RT protocol and
technical advancement created a possibility for improve-
ment of tolerance and local disease control. For example,
intensity modulated RT (IMRT) resulted in significantly
better disease control (87% vs. 80%) and 2 year survival
> 90% without increase in toxicity14. Novel approach is
an introduction of targeted therapy, such as anti-EGFR
monoclonal antibody, cetuximab. Concomitant cetuxi-
mab with RT achieves 13% higher 3 year survival, pro-
longation of median survival from 29.3 to 49 months and
8% better locoregional disease control in comparison to
administration of single RT modality. Tremplin study
compared CCRT with cisplatin and cetuximab, in both
cases after ICT with TPF and revealed comparable re-
sults, with significantly higher tolerance in cetuximab
group (71% vs. 43%)15. These promising results give fu-
ture consideration for ICT with TPF and CCRT cetu-
ximab based therapy as a new standard in treatment of
advanced laryngeal carcinoma1.
Therefore non-surgical methods of treatment of ad-
vanced laryngeal carcinoma are constantly changing and
improving as new chemotherapeutics are being intro-
duced into protocols. Although satisfactory results of la-
ryngeal preservation have been achieved, multiple ad-
verse effects of treatment should not be neglected. When
RT, ICRT or ICT are compared, mucositis of 3rd and 4th
grade is significantly more frequent in ICRT arm (43%
vs. 24% u RT). Incidence of acute toxicity of 3rd and 4th
grade is significantly more frequent in ICRT (82%) and
ICT (81%) arm then in RT arm. TPF protocol is accompa-
nied by specific adverse effects such as neutropenia of
3rd and 4th grade, thrombocytopenia, lethargy and fe-
brile neutropenia (12% vs. 7% in PF group, p=0.04). In
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order to prevent aforementioned potentially life threat-
ening complications, patients on TPF protocol prophy-
lactically receive G-CSF which significantly lowers the
frequency of adverse effects (11% vs. 22%). Nausea, ane-
mia, stomatitis, anorexia and diarrhea may also appear
as early adverse effects. Late adverse effects are a partic-
ular problem in RT and ICRT. They are defined as 3rd
and 4th grade toxicity of duration longer than 180 days
from the beginning of treatment, larynx or pharynx dys-
function, dependence on nasogastric tube longer than 2
years or need for gastrostoma, as well as death, caused
not by progression of the malignant disease whereby la-
ryngeal dysfunction is one of the contributing factors.
Late adverse effects appear in 43% of patients. The most
frequent is pharyngeal dysfunction (27%), nasogastric
tube nutrition (13%), laryngeal dysfunction (12%) and
death (10%). Multivariate analyses have shown that older
age, higher TNM stage and neck dissection after RT are
risk factors for development of late complications16.
Interestingly, some adverse effects such as cetuximab
associated rash can be of prognostical value. Patients
that develop rash have statistically significant longer
survival (68,8 vs. 25,6 months, HR 0,49, p= 0.002)17.
However in 2006 Hoffmann et al. noticed that for the
last two decades overall survival had risen for all tumor
sites except for larynx 18. That was accompanied with
higher percentage of patients treated with non-surgical
methods. Moreover, overall survival of patients with
T3N0M0 stage declined18. Chen and Haplern showed in
their 2007 study a significantly higher survival in pa-
tients after TL compared to patients treated with RT
or/and CCRT, especially in cohort with T4 tumors19. De-
tailed analysis of studies advocating non-surgical meth-
ods of treatment showed large and numerous deficien-
cies. Some of them are: tumor site distribution didn’t
correspond with real distribution (supraglottis was more
frequently involved than glottis), definition of advanced
laryngeal carcinoma was unclear, patients with mobile
vocal cords were grouped together with advanced laryn-
geal carcinoma patients, patients with/without arytenoid
fixation were not separated, patients were young and
healthy (more than 80% of patients had Karnofsky score
>90) and rare patients had advanced metastatic neck
disease... Uncritical enthusiasm with non-surgical meth-
ods of treatment resulted in higher incidence of treat-
ment toxicities, higher rates of »salvage surgery« with
more frequent adverse effects than compared to initial
TL (slower healing, stenosis, fistula, pharyngeal and la-
ryngeal edema), lower number of partial laryngectomies
and lower overall rate of disease cure18.
That resulted in a consensus attempt around »LPS«
project with reevaluation of clinical studies and uniform
recommendations for future studies. Kian Ang et al. con-
cluded that the best results are achieved in patients with
T2–T3 tumors, without signs of laryngeal dysfunction
and who are not candidates for partial laryngectomy. T4
tumors, especially those with cartilage and neck soft tis-
sue infiltration, are not the candidates for LPS (odds ra-
tio for response on chemotherapy of T1–T3 tumors vs. T4
tumors is 5.6 p=0.0108). With regards to T2 tumors, the
conclusion was that patients who are not candidates for
PL should undergo LPS. The grade of preservation and
function of larynx should be evaluated for speech (Voice
Handicap Index-10) and swallowing (radiogram) up to 2
years after the end of therapy. In order to unify research
and enable results comparison, working group defined 2
sets of goals: primary (cure, survival and preservation of
function) and secondary (laryngharyngeal dysfunction
free period, overall survival, locoregional control, time to
tracheotomy or TL and quality of life)20.
When choosing appropriate therapy for oncological
patient, quality of life (QOL) is a special category to be
taken into account besides complications, pain, duration
of treatment and overall benefit for the patient. Various
studies have been conducted that compared different
consequences of treatment and their effect on patient
QOL. Fung et al. evaluated the effect of LPS on speech
and swallowing. Results showed that patients with pre-
served larynx have better QOL in connection with speech
and higher probability of sustaining per oral nutrition
without nutrition supplements21. Hanna et al. didn’t find
statistically significant difference in overall quality of life
in patients with and without larynx (whereby QOL was
measured by EORTC QLQ H&H35 questionnaire). They
concluded that every modality of therapy carried specific
consequences of treatment with diminishing impact on
QOL22.
Numerous molecular studies are currently being con-
ducted with regards to head and neck squamous cellular
carcinoma with the main goal to discover prognostical
markers and/or potential therapy targets.
Aforementioned cetuximab is one example. The exci-
sion repair cross-complementation group 1 (ERCC1) en-
zyme participates in DNA reparation and preliminary re-
search shows that ERCC1 negative tumors could better
react on ICT than ERCC1 positive tumors23. Disruptive
TP53 mutation is a negative prognostic factor and such
patients show shorter survival, however further research
is necessary for unequivocal results24. In conclusion,
treatment should be individualized for each patient with
regards to: overall patient condition, stage of the disease,
numerous sociological and culturological aspects, techni-
cal possibilities of the treatment facility...Novel studies,
especially large multicentric uniform studies are neces-
sary in order to establish the standard method of treat-
ment as well as to continuously improve the treatment of
laryngeal carcinoma.
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NOVI NA^INI LIJE^ENJE LARINGEALNOG KARCINOMA
S A @ E T A K
Rani karcinomi larinksa uklju~uju stadije T1 i T2. Otvorene funkcijske operacije dosti`u lokalnu kontrolu bolesti
kod 90–95% T1 tumora te kod 70–90% T2 tumora. Primarna radioterapija posti`e lokalnu kontrolu kod 85–94% T1
tumora te 70–80% kod T2 tumora. Uvo|enje endoskopske laserske kirurgije je rezultiralo daljnom popularizacijom
prezervacijske kirurgije, gdje se jednaki rezultati posti`u na minimalno invazivni na~in. S druge strane, zlatni standard
u lije~enju uznapredovalog karcinoma je bila totalna laringektomija sa disekcijom vrata, pra}ena radioterapijom. Ukup-
no petogodi{enje pre`ivljenje je bilo oko 50%. Zbog utjecaja TL na kvalitetu `ivota »Larynx preservation strategy«
(LPS) je razvijena u ranim devedestetim godinama 20. st. Novi modaliteti tako|er uklju~uju ciljanu terapiju, kao anti-
-EGFR monoklonalno protutijelo, cetuximab. Konkomitantni cetuximab i RT posti`e ve}e pre`ivljenje i bolju lokoregio-
nalnu kontrolu u usporedbi samo sa RT.
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